[ad_1]
October is Breast Cancer Awareness Month, an annual educational and fundraising campaign targeting the second leading cause of cancer death among women.
Organizations, clinicians, cancer survivors and patients, and breast cancer survivors, and the treatment of cancer.
In recognition of Breast Cancer Awareness Month, HemOnc Today Cancer, including breast reconstruction, financial toxicity, and treatment.
- Inviting women to mammography can reduce breast cancer mortality by up to 20%. However, the reduction appeared limited to women who could benefit from screening. READ MORE.
- Women with breast cancer has a significant role in the treatment of cancer. READ MORE.
- Postmenopausal women who have lost weight over 3 years. READ MORE.
- The percentage of patients with breast cancer who receive their diagnosis in the past decade. About two-thirds of patients diagnosed with breast cancer READ MORE.
- Atezolizumab (Tecentriq, Genentech) has been shown to be safe and effective in patients with metastatic triple-negative breast cancer. Researchers observed the most significant survival benefit from aterolizumab as first-line therapy, and from those with higher levels of tumor-infiltrating immune cells and PD-L1-positive immune cells. READ MORE.
- Women who underwent autologous fat transfer for breast cancer surgery did not appear at increased risk for local recurrence. Fat transfer reconstruction was also associated with lower mortality rates than conventional breast reconstruction. READ MORE.
- An online prognostic tool is very close to recurrence between ER-positive breast cancer. The Clinical Treatment Score post-5 years could be used to determine whether patients should continue endocrine therapy 5 years after initial treatment. READ MORE.
- More than half of a small cohort of women with early-stage, BRCA-positive breast cancer who received talazoparib (BMN-673; Pfizer) – oral poly (ADP-ribose) polymerase (PARP) inhibitor – once daily before surgery. READ MORE.
- Female nursing home patients who underwent breast cancer surgery experienced significant functional decline and high rates of 1-year mortality. READ MORE.
- Whole-exome sequencing identified MSH6 and ATM possible moderate-risk predisposition genes for breast cancer. READ MORE.
[ad_2]
Source link
